PMV Pharma Q2 net loss $17.4M; FDA aligns on Phase 2 dose for PC14586

PMV Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.80

Cash, equivalents & marketable securities $218.8M as of June 30, 2023, down from $277.4M a year ago.
Net loss for six months ended June 30, 2023 was $36.6M vs. $35.7M in same period 2022.
R&D expenses rose to $28.9M for six months, driven by headcount and clinical costs for PC14586.
FDA alignment obtained on recommended Phase 2 dose and key elements of registrational trial; Phase 1 data update expected 2H 2023.
Appointed Dr. Masha Poyurovsky as Vice President of Biology; ongoing combination arm with KEYTRUDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported Six months ended June 30, 2023 results: net income -$36.6 million.

Period: Six months ended June 30, 2023
Net income: -$36.6 million
Result: reported results

Exact text from the filing

Net loss for the six months ended June 30, 2023, was $36.6 million compared to $35.7 million for the six months ended June 30, 2022.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.